Nisa Investment Advisors LLC Buys 2,723 Shares of West Pharmaceutical Services, Inc. $WST

Nisa Investment Advisors LLC increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 7.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,551 shares of the medical instruments supplier’s stock after buying an additional 2,723 shares during the period. Nisa Investment Advisors LLC’s holdings in West Pharmaceutical Services were worth $9,851,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in WST. Integrated Wealth Concepts LLC increased its stake in shares of West Pharmaceutical Services by 34.5% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,287 shares of the medical instruments supplier’s stock worth $736,000 after purchasing an additional 844 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in West Pharmaceutical Services by 51.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,566 shares of the medical instruments supplier’s stock valued at $3,261,000 after purchasing an additional 4,961 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in West Pharmaceutical Services in the first quarter worth $329,000. Empowered Funds LLC raised its stake in shares of West Pharmaceutical Services by 16.1% in the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after buying an additional 224 shares during the period. Finally, Intech Investment Management LLC lifted its position in shares of West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after buying an additional 1,307 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 0.0%

Shares of West Pharmaceutical Services stock opened at $275.26 on Friday. The company’s 50-day moving average price is $273.55 and its 200-day moving average price is $258.07. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12-month low of $187.43 and a 12-month high of $348.90. The company has a market cap of $19.80 billion, a price-to-earnings ratio of 40.78, a PEG ratio of 3.80 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. During the same quarter in the previous year, the company earned $1.85 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 4th. Investors of record on Wednesday, January 28th will be given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 13.04%.

Wall Street Analysts Forecast Growth

WST has been the subject of several recent research reports. Rothschild Redb raised West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, September 15th. Evercore ISI lifted their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Tuesday, October 14th. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a report on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft set a $345.00 price objective on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $335.78.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.